Trials
2 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- DMD (2 trials), Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease, Musculoskeletal Diseases, Neuromuscular Diseases (NMD), Nervous System Diseases and 9 more
- Main trialPhase 3
- “A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping”In the company’s words, NCT07587242 on ClinicalTrials.gov
Other drugs for DMD
- Givinostat HydrochlorideItalfarmaco · Phase 3
- SGT-003Solid Biosciences Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- SatralizumabRoche · Phase 2
- DS-5141bDaiichi Sankyo · Phase 2
Coming up2
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2029 | A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping | |
| Phase 2Active, not recruiting | 30 Apr 2027 | Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping | |
| Phase 1/2Completed | 25 Nov 2024 | Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026